Analysis of Antibodies to Newly Described Plasmodium falciparum Merozoite Antigens Supports MSPDBL2 as a Predicted Target of Naturally Acquired Immunity

ABSTRACT Prospective studies continue to identify malaria parasite genes with particular patterns of polymorphism which indicate they may be under immune selection, and the encoded proteins require investigation. Sixteen new recombinant protein reagents were designed to characterize three such polymorphic proteins expressed in Plasmodium falciparum schizonts and merozoites: MSPDBL1 (also termed MSP3.4) and MSPDBL2 (MSP3.8), which possess Duffy binding-like (DBL) domains, and SURFIN4.2, encoded by a member of the surface-associated interspersed (surf) multigene family. After testing the antigenicities of these reagents by murine immunization and parasite immunofluorescence, we analyzed naturally acquired antibody responses to the antigens in two cohorts in coastal Kenya in which the parasite was endemic (Chonyi [n = 497] and Ngerenya [n = 461]). As expected, the prevalence and levels of serum antibodies increased with age. We then investigated correlations with subsequent risk of clinical malaria among children <11 years of age during 6 months follow-up surveillance. Antibodies to the polymorphic central region of MSPDBL2 were associated with reduced risk of malaria in both cohorts, with statistical significance remaining for the 3D7 allelic type after adjustment for individuals' ages in years and antibody reactivity to whole-schizont extract (Chonyi, risk ratio, 0.51, and 95% confidence interval [CI], 0.28 to 0.93; Ngerenya, risk ratio, 0.38, and 95% CI, 0.18 to 0.82). For the MSPDBL1 Palo Alto allelic-type antigen, there was a protective association in one cohort (Ngerenya, risk ratio, 0.53, and 95% CI, 0.32 to 0.89), whereas the other antigens showed no protective associations after adjustment. These findings support the prediction that antibodies to the polymorphic region of MSPDBL2 contribute to protective immunity.

[1]  D. Kaslow,et al.  Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities. , 2013, Vaccine.

[2]  A. Cowman,et al.  Modulation of PF10_0355 (MSPDBL2) Alters Plasmodium falciparum Response to Antimalarial Drugs , 2013, Antimicrobial Agents and Chemotherapy.

[3]  Hong Zhou,et al.  Overcoming Allelic Specificity by Immunization with Five Allelic Forms of Plasmodium falciparum Apical Membrane Antigen 1 , 2013, Infection and Immunity.

[4]  Danny W. Wilson,et al.  Defining the Antigenic Diversity of Plasmodium falciparum Apical Membrane Antigen 1 and the Requirements for a Multi-Allele Vaccine against Malaria , 2012, PloS one.

[5]  D. Kwiatkowski,et al.  Population Genomic Scan for Candidate Signatures of Balancing Selection to Guide Antigen Characterization in Malaria Parasites , 2012, PLoS genetics.

[6]  Brian J. Smith,et al.  Insights into Duffy Binding-like Domains through the Crystal Structure and Function of the Merozoite Surface Protein MSPDBL2 from Plasmodium falciparum* , 2012, The Journal of Biological Chemistry.

[7]  Pardis C Sabeti,et al.  Sequence-based association and selection scans identify drug resistance loci in the Plasmodium falciparum malaria parasite , 2012, Proceedings of the National Academy of Sciences.

[8]  John C. Tan,et al.  Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing , 2012, Nature.

[9]  K. L. Le Roch,et al.  Genomics and integrated systems biology in Plasmodium falciparum: a path to malaria control and eradication , 2012, Parasite immunology.

[10]  J. Adams,et al.  Design and Immunogenicity of a Novel Synthetic Antigen Based on the Ligand Domain of the Plasmodium vivax Duffy Binding Protein , 2011, Clinical and Vaccine Immunology.

[11]  A. Thomas,et al.  A Malaria Vaccine Based on the Polymorphic Block 2 Region of MSP-1 that Elicits a Broad Serotype-Spanning Immune Response , 2011, PloS one.

[12]  D. Conway,et al.  A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1 , 2011, Vaccine.

[13]  Dominic P. Kwiatkowski,et al.  BASIGIN is a receptor essential for erythrocyte invasion by Plasmodium falciparum , 2011, Nature.

[14]  Kazuhide Yahata,et al.  PEXEL-independent trafficking of Plasmodium falciparum SURFIN4.2 to the parasite-infected red blood cell and Maurer's clefts. , 2011, Parasitology international.

[15]  Daniel L. K. Yamins,et al.  Identification and Functional Validation of the Novel Antimalarial Resistance Locus PF10_0355 in Plasmodium falciparum , 2011, PLoS genetics.

[16]  Simon I. Hay,et al.  Stable and Unstable Malaria Hotspots in Longitudinal Cohort Studies in Kenya , 2010, PLoS medicine.

[17]  X. Su,et al.  Recent Progress in Functional Genomic Research in Plasmodium falciparum , 2010, Current genomics.

[18]  D. Conway,et al.  Allele Frequency–Based and Polymorphism-Versus-Divergence Indices of Balancing Selection in a New Filtered Set of Polymorphic Genes in Plasmodium falciparum , 2010, Molecular biology and evolution.

[19]  Rodrigo Lopez,et al.  A new bioinformatics analysis tools framework at EMBL–EBI , 2010, Nucleic Acids Res..

[20]  Jack S. Richards,et al.  The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis , 2010, PLoS medicine.

[21]  Christopher G. Adda,et al.  Recombinant protein vaccines against the asexual blood-stages of Plasmodium falciparum , 2010, Human vaccines.

[22]  A. Thomas,et al.  Humoral Immune Response to Mixed PfAMA1 Alleles; Multivalent PfAMA1 Vaccines Induce Broad Specificity , 2009, PloS one.

[23]  C. Blanc,et al.  Toward the Rational Design of a Malaria Vaccine Construct Using the MSP3 Family as an Example: Contribution of Antigenicity Studies in Humans , 2009, Infection and Immunity.

[24]  P. Druilhe,et al.  Toward the Rational Design of a Malaria Vaccine Construct Using the MSP3 Family as an Example: Contribution of Immunogenicity Studies in Models , 2009, Infection and Immunity.

[25]  Virander S. Chauhan,et al.  A novel Plasmodium falciparum erythrocyte binding protein associated with the merozoite surface, PfDBLMSP. , 2009, International journal for parasitology.

[26]  D. Conway,et al.  Prospective Identification of Malaria Parasite Genes under Balancing Selection , 2009, PloS one.

[27]  J. Barnwell,et al.  A Conserved Multi-Gene Family Induces Cross-Reactive Antibodies Effective in Defense against Plasmodium falciparum , 2009, PloS one.

[28]  D. Conway,et al.  Breadth and Magnitude of Antibody Responses to Multiple Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Clinical Malaria , 2008, Infection and Immunity.

[29]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[30]  Andrea Crisanti,et al.  Profiling the antibody immune response against blood stage malaria vaccine candidates. , 2007, Clinical chemistry.

[31]  D. Conway,et al.  Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. , 2007, The Journal of infectious diseases.

[32]  Ole Lund,et al.  Epitope Mapping and Topographic Analysis of VAR2CSA DBL3X Involved in P. falciparum Placental Sequestration , 2006, PLoS pathogens.

[33]  D. Conway,et al.  High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. , 2006, Vaccine.

[34]  M. Wahlgren,et al.  SURFIN is a polymorphic antigen expressed on Plasmodium falciparum merozoites and infected erythrocytes , 2005, The Journal of experimental medicine.

[35]  R. Snow,et al.  Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. , 2005, The Journal of infectious diseases.

[36]  D. Conway,et al.  Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. , 2004, Vaccine.

[37]  Christopher J. Tonkin,et al.  Localization of organellar proteins in Plasmodium falciparum using a novel set of transfection vectors and a new immunofluorescence fixation method. , 2004, Molecular and biochemical parasitology.

[38]  Patricia De la Vega,et al.  Discovery of Gene Function by Expression Profiling of the Malaria Parasite Life Cycle , 2003, Science.

[39]  J. Derisi,et al.  The Transcriptome of the Intraerythrocytic Developmental Cycle of Plasmodium falciparum , 2003, PLoS biology.

[40]  D. Conway,et al.  Repeat Sequences in Block 2 of Plasmodium falciparum Merozoite Surface Protein 1 Are Targets of Antibodies Associated with Protection from Malaria , 2003, Infection and Immunity.

[41]  David L. Tabb,et al.  A proteomic view of the Plasmodium falciparum life cycle , 2002, Nature.

[42]  D. Conway,et al.  A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses , 2000, Nature Medicine.

[43]  G. McVean,et al.  Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome , 2007, Nature Genetics.

[44]  W H TALIAFERRO,et al.  Acquired immunity in malaria. , 1948, Abstracts. International Congress on Tropical Medicine and Malaria.